Plain-English translation of NCT07304128 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer medication called in people with advanced solid tumors (cancers that have spread and are difficult to treat). The study will determine how safe this medication is, what side effects it causes, and how well it works. Researchers are particularly interested in tumors that have a specific protein marker called CLDN6.
Many patients with advanced solid tumors — including ovarian cancer, lung cancer, and testicular cancer — don't respond well to standard treatments or can't tolerate them. This medication represents a new approach to fighting these cancers, and this study will help doctors understand whether it's safe and effective enough to use in future patients.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an infusion at a medical center, starting at a low dose and gradually increasing as the study progresses (if you're in the first part) or at a specific dose (if you're in the second part). You'll have regular visits to the hospital or clinic for blood tests, imaging scans, and checkups to monitor how you're responding and watch for side effects. The study involves about 100 participants across multiple centers, and you'll be monitored closely throughout your participation.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Primelink BioTherapeitics(ShenZhen) Limited
Enrollment target
~100 participants
Started
February 2026
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yi Xu
Primelink BioTherapeitics(ShenZhen) Limited
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.